Oncolytics Biotech Files 6-K Report

Ticker: ONCY · Form: 6-K · Filed: Sep 19, 2024 · CIK: 1129928

Oncolytics Biotech INC 6-K Filing Summary
FieldDetail
CompanyOncolytics Biotech INC (ONCY)
Form Type6-K
Filed DateSep 19, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, foreign-private-issuer, regulatory

Related Tickers: ONCY

TL;DR

Oncolytics Biotech (ONCY) filed a 6-K, just a routine foreign issuer report, no major news.

AI Summary

Oncolytics Biotech Inc. filed a Form 6-K on September 19, 2024, reporting as a foreign private issuer. The company is based in Calgary, Alberta, Canada, and operates in the Pharmaceutical Preparations sector. This filing is made pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.

Why It Matters

This filing indicates Oncolytics Biotech Inc. is complying with SEC reporting requirements for foreign private issuers, providing transparency to investors about its corporate status and regulatory adherence.

Risk Assessment

Risk Level: low — A Form 6-K is typically a routine filing for foreign private issuers and does not usually contain material non-public information that would significantly alter risk.

Key Players & Entities

FAQ

What type of filing is this Form 6-K?

This Form 6-K is a Report of Foreign Private Issuer.

Who is the filer of this report?

The filer is ONCOLYTICS BIOTECH INC.

On what date was this Form 6-K filed?

The Form 6-K was filed on September 19, 2024.

Where is ONCOLYTICS BIOTECH INC. located?

ONCOLYTICS BIOTECH INC. is located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada.

What is the Standard Industrial Classification code for this company?

The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2024-09-19 07:01:30

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date September 19, 2024 Kirk Look Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing